Bitcoin -102.88
$8,645.67 -1.19%
Ethereum -2.73
$184.25 -1.48%
Zcash -0.36
$36.41 -0.99%
Monero 0.63
$65.21 0.97%
Tether 0.00
$1.00 -0.05%
Stellar 0.00
$0.07 -2.81%
Dendritic Cell-Targeting Therapeutic Vaccine

CRPT Rating: 2.2

  • Team & Advisory Board
  • Product & Research
  • Idea
  • Marketing
  • Investors Security
View Detailed Rating Website Whitepaper

We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases. Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile. The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.

Token Sale: —
Ticker
ICO Token Price
Whitelist
Min/Max Personal Cap
Accepts
Hardcap

CRPT Rating (?) : 2.2


  • Team & Advisory Board
    • TEAM (2.4)
      • Leading Technological Experts (3)
      • Project Leader (1)
      • Development Team lead (1)
      • Marketing Lead (2)
      • Specification of experts work (3)
      • Experts Experience of in their spheres (3)
      • Presence of all necessary experts (3)
    • Advisory Board (2.5)
      • Popularity of advisors (3)
      • Expertise of advisors to the project profile (2)
  • Product Description & Marketing Research
    • Product Description (1.5)
      • Roadmap (1)
      • Detalization of product description (1)
      • Regularity of github commits (1)
      • Presence of product beta version (1)
      • Token description and role (2)
      • Discounts on goods and services (2)
      • Possibility of the project management via dao (1)
      • Devidents reception from tokens (2)
      • Buyout of tokens from investors (2)
      • Commision for tokens usage (1)
      • Profit calculation is present and adequate (2)
      • Financial plan detalization (2)
      • Tokens spending ratio (3)
    • Marketing Research (2.4)
      • Lack of competitors (2)
      • Lack of ready made products (1)
      • Presence of technological advantages (1)
      • The amount of financing attracted by competitors (3)
      • Dynamics of competitors growth (3)
      • Jurisdiction research (3)
      • Legal disclaimer for duties and obligations (3)
  • Idea (2.4)
    • Adequacy of the idea (3)
    • Originality of the idea (1)
    • Value of the idea for the community (3)
  • Marketing (2.8)
    • Website (3)
    • Social networks (3)
    • Marketing plan (3)
    • Marketing team (2)
    • Public presence of the team (3)
  • Investors Security (1.7)
    • Daico (1)
    • Decentralized escrow (3)



Short review
Number of team Members

Add a Comment

Member of The Internet Defense League